- Home
- ACAD vs PTCT Comparison
ACAD vs PTCT Comparison
Compare ACAD & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- PTCT
- Stock Information
- Founded
- ACAD 1993
- PTCT 1998
- Country
- ACAD United States
- PTCT United States
- Employees
- ACAD N/A
- PTCT N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- ACAD Health Care
- PTCT Health Care
- Exchange
- ACAD Nasdaq
- PTCT Nasdaq
- Market Cap
- ACAD 3.5B
- PTCT 3.9B
- IPO Year
- ACAD 2004
- PTCT 2013
- Fundamental
- Price
- ACAD $23.53
- PTCT $52.13
- Analyst Decision
- ACAD Buy
- PTCT Buy
- Analyst Count
- ACAD 18
- PTCT 14
- Target Price
- ACAD $27.94
- PTCT $67.64
- AVG Volume (30 Days)
- ACAD 1.7M
- PTCT 1.2M
- Earning Date
- ACAD 08-06-2025
- PTCT 08-07-2025
- Dividend Yield
- ACAD N/A
- PTCT N/A
- EPS Growth
- ACAD N/A
- PTCT N/A
- EPS
- ACAD 1.37
- PTCT 7.51
- Revenue
- ACAD $996,283,000.00
- PTCT $1,772,758,000.00
- Revenue This Year
- ACAD $13.28
- PTCT $120.38
- Revenue Next Year
- ACAD $10.88
- PTCT N/A
- P/E Ratio
- ACAD $17.19
- PTCT $6.94
- Revenue Growth
- ACAD 22.42
- PTCT 91.12
- 52 Week Low
- ACAD $13.40
- PTCT $29.02
- 52 Week High
- ACAD $25.23
- PTCT $58.38
- Technical
- Relative Strength Index (RSI)
- ACAD 61.47
- PTCT 62.66
- Support Level
- ACAD $22.40
- PTCT $44.15
- Resistance Level
- ACAD $24.06
- PTCT $52.70
- Average True Range (ATR)
- ACAD 0.72
- PTCT 1.87
- MACD
- ACAD 0.09
- PTCT 0.59
- Stochastic Oscillator
- ACAD 76.96
- PTCT 93.33
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.